🐦 推特Wall St EngineDoubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 04:20:10·⟳ 抓取 04:20:14 +4s·⚡ 决策 10-22 04:42:35 +22m21s·6.0 天前
Molina Healthcare(MOH)Q3’26业绩：营收/调整后EPS超预期但同比腰斩、全年保费指引低于共识，盘后跌约5%——与20:36已研判为同一事件
20:36 UTC本臂已就同一份Molina Healthcare Q3’26财报（seeking_alpha源，含相同EPS/营收/指引数据）做出研判（结论为值得做，并已记录盘后约-5.4%、先例次日续跌）；本条20:20 UTC的X(Wall St Engine)帖子仅为同一财报的社媒摘要，无新增金额、指引修正或官方新表态，属同一具体催化的重复信号，再发一条ENTER会造成同事件重复建仓，故AVOID。
📄 原文Wall St Engine@wallstengine↗ 原文
MOLINA HEALTHCARE $MOH Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $11.08B (Est. $10.81B) 🟢 🔹 Adj. EPS: $0.89 (Est. $0.74) 🟢;…
不做 Molina Healthcare（MOH.US）
重复信号：本条X(Wall St Engine, 20:20 UTC)与本臂20:36 UTC已研判的Molina Healthcare Q3’26财报（seeking_alpha）为同一具体催化，EPS/营收/指引/Florida与MAPD亏损等事实完全一致，无任何新增信息；该事件的交易结论（含盘后约-5%反应与先例次日续跌）已由前一条记录承载，不再重复开仓。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
X帖内容与4分钟前已处理的MOH Q3’26财报信号为同一事件、数字一致且无增量信息；盘后已跌至约$204.5(-4.8%)，该催化的交易决策已由前一条记录承载，本条按去重不做。
消息传播链
- 节点
- 节点
- 节点
关键理由
- 同一Q3’26财报催化已在20:36 UTC被处理并形成交易结论，本社媒帖不带来任何会改变方向、标的或价位的新增事实。
主要风险
- 若公司随后发布指引修正/补充声明则构成新事件，需脱离去重另行研判；本条不承载该判断。
先例如何影响了这次决策
对本次决策的影响:本条在跨源查重阶段即命中同一具体催化且无新增事实，按去重复核不再独立检索/调用历史先例；前一条已处理记录已自行承载先例与交易判断。
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 2,345 ms
{"result": "search_processed_events:agent query=`moh third quarter 2026 guidance medicaid margin florida | molina healthcare q3 2026 earnings results eps beat mcr | molina healthcare q3'26 earnings revenue $11.08b`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、26912 条本臂决策(完整)，返回 7 条候选。\n• 10-21 20:36 UTC(北京 1 - stock_quote 成功 stock_tools HTTP · 144 ms
{ - web_search 成功 doubao_search · 1,609 ms
豆包搜索结果（原始查询:Molina Healthcare MOH Q3 2026 earnings results stock reaction guidance；API SearchType:web）
原文全文
展开原文 · 1,194 字
MOLINA HEALTHCARE $MOH Q3’26 EARNINGS HIGHLIGHTS
🔹 Revenue: $11.08B (Est. $10.81B) 🟢
🔹 Adj. EPS: $0.89 (Est. $0.74) 🟢; -53% YoY
🔹 GAAP EPS: $0.73; -52% YoY
🔹 Premium Revenue: $10.46B; -4% YoY
🔹 MCR: 92.9%
FY26 Guide:
🔹 Premium Revenue: ~$42B
🔹 GAAP EPS: At least $2.38
🔹 Adj. EPS: At least $5.25
Segment Premium Revenue:
🔹 Medicaid: $8.2B
🔹 Medicare: $1.62B
🔹 Marketplace: $642M
Segment MCR:
🔹 Medicaid: 93.0%
🔹 Medicare: 93.0%
🔹 Marketplace: 92.5%
Other Q3 Metrics:
🔹 G&A Ratio: 6.4%
🔹 Members: ~4.9M
🔹 Days in Claims Payable: 44
🔹 Parent Cash & Investments: ~$608M
Key Updates:
🔸 Amortization of intangible assets: $0.19/share
🔸 Income tax effect: -$0.03/share
🔸 Full year guidance includes a loss of $1.50 per share due to the implementation of the new Florida Medicaid contract in the fourth quarter of 2026 and a loss of $1.00 per share due to performance of the traditional MAPD product, which the Company previously announced it will exit for 2027.
Comments:
🔸 “With the apparent plateauing of medical cost trend, which remains at elevated levels, and the strength of recent rate updates for 2027, we believe we are likely observing the beginning of the turn in Medicaid margins.”
🔹 Revenue: $11.08B (Est. $10.81B) 🟢
🔹 Adj. EPS: $0.89 (Est. $0.74) 🟢; -53% YoY
🔹 GAAP EPS: $0.73; -52% YoY
🔹 Premium Revenue: $10.46B; -4% YoY
🔹 MCR: 92.9%
FY26 Guide:
🔹 Premium Revenue: ~$42B
🔹 GAAP EPS: At least $2.38
🔹 Adj. EPS: At least $5.25
Segment Premium Revenue:
🔹 Medicaid: $8.2B
🔹 Medicare: $1.62B
🔹 Marketplace: $642M
Segment MCR:
🔹 Medicaid: 93.0%
🔹 Medicare: 93.0%
🔹 Marketplace: 92.5%
Other Q3 Metrics:
🔹 G&A Ratio: 6.4%
🔹 Members: ~4.9M
🔹 Days in Claims Payable: 44
🔹 Parent Cash & Investments: ~$608M
Key Updates:
🔸 Amortization of intangible assets: $0.19/share
🔸 Income tax effect: -$0.03/share
🔸 Full year guidance includes a loss of $1.50 per share due to the implementation of the new Florida Medicaid contract in the fourth quarter of 2026 and a loss of $1.00 per share due to performance of the traditional MAPD product, which the Company previously announced it will exit for 2027.
Comments:
🔸 “With the apparent plateauing of medical cost trend, which remains at elevated levels, and the strength of recent rate updates for 2027, we believe we are likely observing the beginning of the turn in Medicaid margins.”
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
8d723761c6· 2026-10-22 04:42 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前